Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02XJI
|
|||
| Former ID |
DAP001067
|
|||
| Drug Name |
Emedastine
|
|||
| Synonyms |
Emadine; Emedastina; Emedastinum; Emedastine [INN]; Emedastine difumarate; KB 2413; KG 2413; Emadine (TN); Emedastina [INN-Spanish]; Emedastine (INN); Emedastine [INN:BAN]; Emedastinum [INN-Latin]; KB-2413; KG-2413; 1-(2-Ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate; 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole; 1-Methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazo)-2-yl)(1,4)diazepane; 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Allergic conjunctivitis [ICD-11: 9A60.02; ICD-10: H10.1] | Approved | [1], [2] | |
| Therapeutic Class |
Antiallergic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H26N4O
|
|||
| Canonical SMILES |
CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C
|
|||
| InChI |
1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3
|
|||
| InChIKey |
KBUZBQVCBVDWKX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 87233-61-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9987, 5141493, 7979153, 8152043, 14873901, 29222360, 46505109, 50065339, 50125935, 57321665, 80764337, 85209785, 92729820, 96024586, 99313639, 103181919, 103930547, 104302873, 125667493, 126683771, 128359814, 134338325, 135259856, 137005450, 142097605, 160964418, 162179114, 164846151, 172913626, 175266282, 177749285, 178103749, 179151350, 223683793, 223743951, 226416763, 241151611, 250027601, 252348848
|
|||
| ChEBI ID |
CHEBI:4779
|
|||
| ADReCS Drug ID | BADD_D00763 ; BADD_D00764 | |||
| SuperDrug ATC ID |
S01GX06
|
|||
| SuperDrug CAS ID |
cas=087233612
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7174). | |||
| REF 2 | Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. | |||
| REF 3 | Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.